1. Home
  2. ICCM vs CELU Comparison

ICCM vs CELU Comparison

Compare ICCM & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IceCure Medical Ltd.

ICCM

IceCure Medical Ltd.

HOLD

Current Price

$0.69

Market Cap

45.5M

Sector

N/A

ML Signal

HOLD

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$1.96

Market Cap

56.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICCM
CELU
Founded
2006
2016
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.5M
56.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ICCM
CELU
Price
$0.69
$1.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$2.50
$6.00
AVG Volume (30 Days)
400.3K
65.1K
Earning Date
11-19-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,975,000.00
$40,578,000.00
Revenue This Year
$2.92
N/A
Revenue Next Year
$57.81
$76.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.59
$1.00
52 Week High
$1.66
$4.35

Technical Indicators

Market Signals
Indicator
ICCM
CELU
Relative Strength Index (RSI) 41.99 55.41
Support Level $0.67 $1.62
Resistance Level $0.72 $2.18
Average True Range (ATR) 0.05 0.14
MACD 0.01 0.04
Stochastic Oscillator 62.50 60.76

Price Performance

Historical Comparison
ICCM
CELU

About ICCM IceCure Medical Ltd.

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: